|

Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy

RECRUITINGN/ASponsored by China Medical University Hospital
Actively Recruiting
PhaseN/A
SponsorChina Medical University Hospital
Started2025-04-07
Est. completion2026-08-31
Eligibility
Age20 Years – 65 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07503496

Summary

This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.

Eligibility

Age: 20 Years – 65 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Breast cancer stage I-III

Exclusion Criteria:

* pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements

Conditions5

Breast CancerBreast Cancer Stage IIIBreast Cancer Stages IBreast Cancer Stages IICancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.